Li fraumeni syndrome
Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant, hereditary disorder that predisposes carriers to early-onset cancers. The syndrome was first described by American physicians Frederick Pei Li and Joseph F. Fraumeni Jr. in 1969.
Genetics[edit | edit source]
Li-Fraumeni syndrome is caused by mutations in the TP53 gene, which provides instructions for making a protein called tumor protein p53. This protein acts as a tumor suppressor, which means it regulates cell division by keeping cells from growing and dividing too rapidly or in an uncontrolled way. Mutations in the TP53 gene disrupt the function of tumor protein p53, impairing its ability to control cell growth and division. This lack of regulation allows cells to divide in an uncontrolled manner and form tumors.
Clinical Features[edit | edit source]
Individuals with Li-Fraumeni syndrome are at an increased risk of developing multiple types of cancer, often at a young age. These cancers include breast cancer, osteosarcoma, soft tissue sarcoma, brain tumors, adrenocortical carcinoma, and leukemia. The risk of cancer is significantly higher in individuals with LFS than in the general population, and the risk increases with age.
Diagnosis[edit | edit source]
Diagnosis of Li-Fraumeni syndrome is based on clinical criteria, known as the Chompret criteria, and genetic testing. The Chompret criteria include the presence of a TP53 mutation, a family history of cancer, and the occurrence of multiple primary cancers. Genetic testing can confirm the presence of a TP53 mutation.
Management and Treatment[edit | edit source]
Management of Li-Fraumeni syndrome involves regular surveillance for early detection of cancer. This may include physical examinations, blood tests, imaging studies, and other diagnostic tests. Treatment depends on the type and stage of cancer, but may include surgery, radiation therapy, chemotherapy, or targeted therapy.
Prognosis[edit | edit source]
The prognosis for individuals with Li-Fraumeni syndrome varies depending on the type and stage of cancer. Early detection and treatment can improve the prognosis.
See Also[edit | edit source]
| Li fraumeni syndrome Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
